The founder of SiranBio, Dr. Zhiwei Yang was invited£ to University of Kentucky (UK) Medical School to give a seminar titled “siRNA – How it> is changing drug discovery and chronic disease treatment”.  Dr. Yang introdλuced the proprietary platform technologies for siRNA drug discovery, and the recent p<rogresses on SiranBio’s pipeline in chronic hepatitis B, fat control, and hyper¥tension.

siRNA has huge advantages compared to small molecule drug discovery in many as≠pects.  It can be applied to many drug targets that previously considered to be n×on-druggable.  It also greatly expedites the drug developmen¥t process, and increases the success rate.  siRNA drug§s are usually very safe and have super long duration.  Many chronic diseases, such as® hypertension, hyperlipidemia, obesity, and gout can b€e treated one injection in 6-12 months.  Chronic hepatitis B can potentially functioεnal cured by a few months’ treatment.

Cancer is the research interest of many scientistsφ in UK.  Dr. Yang discussed in details with professors and postdoc there on the po'ssible scenarios and technical challenges in this field.  siRNA has many favorable properties <which are ideal for cancer treatments.  They c an be designed specifically targeting for certain mutations, and can be easily prepared as a coλcktail to target several genes simultaneously.  The scie™ntists in UK also shared their recent progresses in cancer research, and discussed the possγible applications of siRNA drugs in cancer treatments.